Molecular Imaging of Ulex Europaeus Agglutinin in Colorectal Cancer Using Confocal Laser Endomicroscopy (With Video)

Weijun Wang¹,²†, Shuxin Tian¹,²,³†, Xin Jiang¹, Suya Pang¹, Huiying Shi¹, Mengke Fan¹, Zeyu Wang¹, Weiwei Jiang¹, Weiqian Hu¹, Xueyan Xiao¹ and Rong Lin¹*

¹ Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ² Department of Gastroenterology, National Health Commission (NHC) Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, the First Affiliated Hospital of Medical College, Shihezi University, Shihezi, China, ³ Department of Gastroenterology, the First Affiliated Hospital of Medical College, Shihezi University, Shihezi, China

Background and Study Aims: Previous studies have identified that colorectal cancer has different fucosylation levels compared to the normal colon. Ulex europaeus agglutinin-I (UEA-I), which specifically combines with α1-2 fucose glycan, is usually used to detect fucosylation levels. Therefore, we used confocal laser endomicroscopy (CLE) to investigate fluorescently labeled UEA-Fluorescein isothiocyanate (FITC) for detecting colonic cancer.

Patients and Methods: We stained frozen mouse colon tissue sections of normal, adenoma, and adenocarcinoma species with UEA-FITC to detect fucosylation levels in different groups. White light endoscopy and endocytoscopy were first used to detect the lesions. The UEA-FITC was then stained in the mice and human colon tissues in vitro. The CLE was used to detect the UEA-FITC levels of the corresponding lesions, and videos were recorded for quantitation analysis. The diagnostic accuracy of UEA-FITC using CLE was evaluated in terms of sensitivity and specificity.

Results: The UEA expression level in colorectal cancer was lower than that in normal intestinal epithelium. The fluorescence intensity ratio of UEA-FITC in colorectal cancer was significantly lower than that in normal tissue detected by CLE in both mice and humans. The combination of UEA-FITC and CLE presented a good diagnostic accuracy with a sensitivity of 95.6% and a specificity of 97.7% for detecting colorectal cancer. The positive and negative predictive values were 91.6% and 95.6%, respectively. Overall, 95.6% of the sites were correctly classified by CLE.

Conclusions: We developed a new imaging strategy to improve the diagnostic efficacy of CLE by using UEA-FITC.

Keywords: colorectal cancer, UEA-FITC, CLE, diagnostic efficacy, colorectal cancer imaging target
INTRODUCTION

Combining cancer-specific molecular imaging technologies with optical imaging agents provides a novel technique for cancer detection. White light endoscopy (WLE) is the initial technique used to detect gastrointestinal tract tumors (1). Nevertheless, WLE has several disadvantages: it is insensitive to detecting multifocal and flat tumors, and is insufficient to judge tumor demarcation lines (2). These disadvantages may affect the detection and complete resection of tumors, which may influence the prognosis of cancer. Cancer-specific molecular imaging agents labeled by fluorescence may augment the distinction between tumors and adjacent normal or benign tissues. Consequently, development of molecular imaging agents that can provide enhanced tumor visualization is of great significance.

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of cancer-related deaths worldwide (3). The global morbidity rate was high at 10.2%, and the mortality rate was high at 9.2% (4). The prognosis of colon cancer is closely related to its clinical stage. The 5-year survival rate for early colon cancer is 90%, and the 5-year survival rate for advanced colon cancer is 14% (5). Therefore, early diagnosis and treatment are essential to improve patient survival.

Colon tumors mostly develop from adenomatous polyps and look similar, but the treatment strategies are completely different (6, 7). Adenomatous polyps can be removed by cold snare polypectomy and endoscopic mucosal resection (EMR); colon tumors can be removed by endoscopic submucosal dissection (ESD), according to the invasion (6). In addition, when deep submucosal infiltration is suspected or confirmed, as the lymph node metastasis increases, the corresponding surgical operations must be performed, and adjuvant chemotherapy may be needed to eradicate the cancer (7). Clinically, appropriate treatment strategies should be selected according to the benign and malignant diseases of the colon.

As the main tool to detect, biopsy, and resect gastrointestinal tumors, WLE has several shortcomings, including difficulty in recognizing flat tumors and difficulty in estimating tumor boundaries (1). Over the past two decades, some novel endoscopic techniques have emerged as promising tools to improve cancer identification and guide endoscopic resection over standard WLE assessment (8–10). Narrow-band imaging (NBI), using a narrowed bandwidth filter (specific blue and green wavelengths), can accentuate structural mucosal patterns and mucosal/submucosal vessels (8). Endocytoscopy (EC) with ultra-high magnification enables in vivo observation of both structural and cellular atypia during routine endoscopic examination (9). Confocal laser endomicroscopy (CLE) is another new enhanced technology. CLE can magnify mucosa up to 1000 times at a subcellular level of resolution up to 250 µm below the mucosal surface using fluorescein as the imaging agent (10). Despite the enhanced images provided by these newly developed technologies, several limitations remain in their applications. For NBI, in some cases, it is not easy to distinguish inflammatory lesions from tumor lesions, thereby contributing to high false-negative rates (11). For EC, the procedure time is prolonged and the recognition theory system has yet to be perfected (12). For CLE, fluorescein stains equally all cell types (including normal cells and cancer cells), and a real-time image version to differentiate cancer may be a great challenge (10).

CLE using a fluorescent-labeled molecular probe has been reported in order to identify colonic dysplasia and cancer (13). Herein, we also attempted to develop a new imaging approach to increase the diagnostic efficacy of the available imaging skills by employing a new fluorescein imaging agent differentially expressed in normal and tumor lesions. Previous studies have identified that colonic cancer has different fucosylation levels than the normal colon (14). Fucosylation is a type of glycosylation modification that adds fucose (6-deoxy-L-galactose) to oligosaccharides/proteins (15). It has been reported that in the absence of fucosylation, dysplasia appeared and proceeded to cancer mainly influencing the right colon and cecum (14). Ulex europaeus agglutinin-1 (UEA-1), which specifically binds to α1-2 fucose glycan, is specifically used to detect fucosylation levels (16).

Therefore, we investigated the expression level of UEA in normal intestinal epithelium and colon cancer, with the purpose of estimating fluorescently labeled UEA-fluorescein isothiocyanate (FITC) as an intestinal imaging agent for detecting colonic cancer with optical imaging.

MATERIALS AND METHODS

Study Design

This study aimed to evaluate UEA as an endoscopic molecular imaging marker for colon cancer. The differential expression of α(1,2) fucosylation in normal colorectal epithelium and colorectal tumor specimens was first demonstrated by UEA-FITC staining in a mouse azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colitis-associated colorectal cancer model. Fluorescently labeled UEA was investigated as a molecular imaging marker to identify colorectal cancer in mouse and human colon specimens. UEA-FITC was administered to the intestinal mucosa, and FITC was detected using CLE.

In mice, an AOM/DSS-induced colitis-associated colorectal cancer model was used, and the detailed methods are provided below. For human colon specimens, all imaged colon specimens were selected on the basis of the endoscopic diagnosis of adenoma or adenocarcinoma. First, WLE was used to detect the susceptive lesions. Then, endocytoscopy and CLE were used to observe the details. All imaged specimens were biopsied and assessed by a pathologist who was blinded to the endoscopic results. For UEA-FITC imaging with CLE, analysis of biopsied regions was reliant on both CLE judgment and histopathology. Histopathological diagnosis was considered the gold standard. This study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. The study was conducted in accordance with the principles of the Declaration of Helsinki.
Animal Experiment
Juvenile male C57BL/6j mice (7 ± 1 weeks old, body weight 20 ± 1 g, Beijing HFK Bio-Technology Co., LTD, China) were housed in individually ventilated cages (four animals per cage) at the SPF facility of Huazhong University of Science and Technology under controlled environmental conditions (temperature 22 ± 2°C; relative humidity 60%–70%) with free access to standard laboratory chow and tap water, and maintained under a regular 12/12-h light/dark cycle. All animal care and experimental procedures were approved by the Animal Care Ministry of Health and were performed in accordance with national and EU guidelines for the handling and use of experimental animals. Animal studies were reported in compliance with the ARRIVE guidelines.

The AOM/DSS-induced colitis-associated colorectal cancer model was developed as previously described (17). Briefly, male mice were treated with AOM (10 mg/kg). Five days later, the mice were fed with 1%-2% DSS for 7 days, followed by regular water drinking for 14 days. This cycle was repeated for three times. During the whole trial, body weight, diarrhea, and macroscopic bleeding of the mice were examined. At the end of the animal experiment, after overnight fasting, mice were sacrificed under anesthesia, and colorectums were collected for WLE, CE, and CLE observation.

Endocytoscopy
All colonoscopic inspections were conducted by well-trained endoscopists (more than 1,500 colonoscopies) using an integrated-type EC (Olympus, Tokyo, Japan). This instrument has a single lens on its tip with a hand lever; the one-touch switch has a 520-fold magnification power from the conventional endoscopic image to ultra-magnification power, without changing the scope. This device has a 520-fold magnification power with a focus depth of 50 μm, which can image the gland duct lumens and the shape of nuclei in the epithelial superficial layer. The images were obtained using 0.05% crystal violet and 1% methylene blue. The intestinal mucosa of mice was examined in vitro because of its narrow lumen, and the human intestinal mucosa was observed in vivo. Uniformly sized fusiform nuclei and roundish lumens regularly represent normal mucosa. Slit-like smooth lumens and uniform fusiform or roundish nuclei indicate adenoma. Vague gland formation and agglomeration of distorted nuclei suggested adenocarcinoma (Figures 2A and 3A).

UEA-FITC Imaging With CLE
After examination by WLE and EC, UEA-FITC staining was used for CLE. Colorectums were washed with saline; then, UEA-FITC (1/50 mg/ml) and IgG-FITC (1/50 mg/ml) were incubated for 2–3 min. Tissue-bound UEA-FITC was detected using a clinical CLE system. This probe-based system (pCLE) (Cellvizio Endomicroscopy System; Mauna Kea Technologies, Paris, France) is commercially available and consists of a flexible miniprobe that may be introduced through the working channel of a standard endoscope. This device was used with a 2.8-mm fiber optic probe. The probe provided a field of view of 240 μm and acquired videos. A typical CLE image of stained normal mucosa displays a hexagonal, honeycomb appearance of vessel architecture along with regular, round luminal openings, surrounded by a homogeneous layer of epithelial cells. Irregular epithelium and villiform- or tubular-shaped crypts all indicate adenoma. Adenocarcinoma causes disorders and destruction of the glands. Videos were taken, and data from entire video sequences (12 frames/s, 10- to 20-s videos) were used for quantitation analysis. For mice, 10 videos from normal mice (n = 10), 19 videos of 19 adenoma specimens from mice with adenoma (n = 5), and 20 videos of 20 tumor specimens from mice with tumors (n = 5) were analyzed. For humans, 10 videos from normal humans (n = 10), six videos of six adenoma specimens from patients with adenoma (n = 6), and four videos of four tumor specimens from patients with tumors (n = 4) were analyzed. To validate the quantitative analysis, we set to cancel the automatic control function of the laser power when using the CLE system. After examination by CLE, representative lesions were biopsied for histopathological correlation.

Statistical Analysis
Statistical analysis was performed using SPSS software. All data are presented as the mean (95% confidence interval). One-way analysis of variance tests were used to determine the significance of UEA expression levels in different groups. For the diagnostic accuracy of UEA-FITC using CLE, sensitivity was calculated as TP/(TP + FN) and specificity was calculated as TN/(TN + FP), where TP equaled the number of true-positive cases, FN equaled the number of false-negative cases, TN equaled the number of true-negative cases, and FP equaled the number of false-positive cases.

RESULTS
UEA-FITC Expression and Distribution
Immunofluorescence was conducted to detect UEA-FITC in frozen mouse tissue sections of normal intestinal epithelium, adenoma, and colorectal tumor; however, the distribution was different (Figure 1A). The single layer of normal intestinal epithelium cells showed widely distributed UEA expression on the mucosal epithelial layer, whereas UEA expression on the mucosal epithelial layer decreased in cancer tissue. Furthermore, the UEA expression level of colorectal adenoma was between them both (Figure 1B). This difference in distribution indicates that UEA may be a feasible agent for the endoscopic molecular imaging of colorectal cancer.

Endoscopic Molecular Imaging for Mice
An ex vivo endoscopic molecular imaging protocol was devised for mice (Figure 2). Fresh mouse colorectums were obtained from a mice AOM/DSS-induced colitis-associated colorectal cancer model (n = 10). For its narrow intestinal cavity, the colorectum was opened longitudinally for the sake of white light visual examination of the intestinal epithelium using a camera.
After spraying 0.05% crystal violet plus 1% methylene blue onto the surface of a polyp or adenocarcinoma together with its surrounding normal mucosa, EC was used to observe the surface of the mucosa. Typical distinct EC images of stained normal mucosa, adenoma, and adenocarcinoma are shown in Figure 2A. Subsequently, a UEA labeled with fluorescein isothiocyanate (FITC) was instilled after washing the mucosa with saline. IgG-FITC was also used as a negative control (Supplementary Figure 1). Colorectums incubated with UEA-FITC and IgG-FITC were imaged using CLE. Normal, adenoma, or adenocarcinoma regions in each colorectum were imaged and biopsied. A pathologist was blinded to the imaging results and analyzed the histologic results. All colorectums were confirmed to have colorectal cancer on the basis of the histologic results. Representative frames of normal intestinal, adenoma, and adenocarcinoma lesions in each colorectum with corresponding histopathology taken by confocal videos are also shown in Figure 2A.
To quantitatively analyze the UEA-FITC signal in confocal videos, the average fluorescence intensity of all frames in the video was calculated as the mean fluorescence intensity. Videos from a normal region, adenoma region, and cancer (endoscopically diagnosed) were applied to determine the fluorescence intensity ratio of UEA-FITC coupling to cancer, adenoma, and normal tissue (Figure 2B). The results showed that the fluorescence intensity ratio of UEA-FITC in cancer tissues was significantly lower than that in normal tissues ($p < 0.05$).

**Endoscopic Molecular Imaging for Humans**

For human colon specimens, all specimens were selected on the basis of endoscopic diagnosis of adenoma or adenocarcinoma ($n = 10$). The adenoma and adenocarcinoma lesions were removed endoscopically by EMR, ESD, or by surgery. The observation procedure for human colorectums was the same as that for mouse colorectums. The colorectums were first investigated by WLE and EC, and then by CLE. After incubation with UEA-
FITC, fiber optic probe was done. IgG-FITC was used for the negative control (Supplementary Figure 1). The lesions were imaged and evaluated by a pathologist who was blinded to the imaging results. All 10 colorectal tumors were pathologically confirmed to have adenomas or cancers by histology. Representative frames from confocal videos taken of adenoma or adenocarcinoma lesions and para-cancer normal tissues with corresponding histopathology are shown in Figure 3A. The average fluorescence intensity of all frames in a confocal video was determined so as to quantitatively analyze the UEA-FITC signal. For each colorectum, videos from a normal region, adenoma region, and cancer were obtained to calculate the fluorescence intensity ratio of UEA-FITC coupling to cancer, adenoma, and normal tissue (Figure 3B). The results showed that compared to normal tissue, the fluorescence intensity ratio of UEA-FITC in cancer was significantly lower ($p < 0.05$).

**Diagnostic Accuracy of UEA-Targeted Imaging**

Confocal images, including mouse and human specimens, were used prospectively to predict the histopathology. Overall, 69 different locations in 20 colorectums, including 20 locations...
from normal mucosa, 25 locations from adenoma, and 24 locations from cancer, were analyzed using a blind method. CLE was applied to evaluate all sites before biopsy, and histological results were compared with CLE judgment. The results of CLE judgment and histology are displayed in Table 1. The sensitivity and specificity of CLE for malignant lesion detection were 95.6% and 97.7%, respectively. The positive and negative predictive values were 91.6% and 95.6%, respectively. The overall correction rate for all sites was 95.6% by the CLE.

**DISCUSSION**

The enhancement of endoscopic detection of colorectal cancer can increase the efficiency of tumor excision and decrease cancer recurrence and progression. Here, we show three main novel findings: (1) UEA is highly expressed in the normal intestinal epithelium but less in colorectal cancer, (2) the combination of UEA-FITC and CLE helped to identify patients with colorectal cancer, and (3) the real-time assessment by CLE conducted on UEA-FITC-targeted locations has a good diagnostic accuracy for colorectal cancer (sensitivity 96.4% and specificity 97.5%).

Previous studies have identified that colonic cancer has different fucosylation levels compared to normal colons (14). It has been reported that α1-3/4 fucosylation in the sera of colon cancer patients was higher than that in other groups (18). However, another study demonstrated that in the deficiency of fucosylation, dysplasia appeared and progressed to adenocarcinoma, mainly affecting the right colon and cecum (14). UEA-I, which combines with α1-2 fucose glycan, is usually used to detect α1-2 fucosylation levels. Our present study demonstrated decreased UEA levels in colonic cancer compared to normal colon tissue (Figure 1). This difference in distribution indicates that UEA may be a feasible agent for the endoscopic molecular imaging of colorectal cancer.

UEA-I is a lectin that specifically couples with α-linked fucose (16). Lectins are highly stereospecific proteins that can recognize numerous sugar structures and interact with glyco-conjugate complexes to form reversible bindings (19). Above all, they are abundantly discovered in plants and animals. Therefore, the UEA-I used here is a safe protein that is suitable for human use, although in our study, it was used in vitro. Furthermore, as the colorectum is a cavity organ, UEA-I can be administered locally without significant systemic absorption. Therefore, UEA-I is a viable and safe target for molecular imaging. The organ imaging protocol developed here facilitates the clinical use of UEA-targeted imaging for the detection and resection of colorectal cancer.

CLE combined with UEA-FITC can reveal differences in the morphology of the staining pattern. As shown in Figures 2A and 3A, a typical CLE image of stained normal mucosa displays a hexagonal, honeycomb appearance of vessel architecture along with regular, round luminal openings, surrounded by a homogeneous layer of epithelial cells. Irregular epithelium and villiform- or tubular-shaped crypts all indicate adenoma. Adenocarcinoma causes disorders and destruction of the glands. These different morphologies could help to diagnose normal, adenoma, and adenocarcinoma lesions in the first step.

In addition, CLE combined with UEA-FITC was investigated for the digital nature of the confocal images, allowing for semi-quantitative analysis. In vivo endoscopic molecular imaging combining fluorescent agents and CLE has also been reported for esophageal lesions (20) and gastric dysplasia (21). In esophageal applications, the addition of a 3-biomarker panel (cyclin A, p53, and aneuploidy) led to a 50% reduction in the false-positive rate of CLE, obtaining a sensitivity of 89.2% and a specificity of 88.9% for any grade of dysplasia, respectively (20). In the gastric study, targeted H-ferritin was demonstrated in resected human early gastric cancers with good diagnostic efficacy (100% sensitivity and 90% specificity) using CLE (21). In previous studies, quantitation was determined using images obtained from video sequences (12 frames/s, 10-20 s videos) were incorporated for analysis. We measured the UEA-FITC fluorescence intensity ratio of tumor tissue to normal tissue using this unbiased method (Figures 2B and 3B).

Although CLE allowed for quantitation, the small field of view impeded efficient examination of the entire colon. WLE was first used to observe the entire colon, then EC was applied to detect suspicious lesions, and CLE was subsequently used. The combination of UEA-FITC and CLE has a good diagnostic accuracy for colorectal cancer (sensitivity 95.6% and specificity 97.7%), which is quite higher than the data reported on CLE alone (sensitivity 81%-91.4% and specificity 76%-85.7%) (22, 23). Estimating the benign and malignant lesions and determining the boundary of the malignant lesions are the key points for the diagnosis and treatment of colorectal cancer. The combination of UEA-FITC and CLE may help improve colorectal cancer detection and the thoroughness of tumor resection.

This study had several limitations. First, this study was limited to an ex vivo investigation, as required by the local ethics committee. However, despite the small number of human specimens, given the experience of our ex vivo human

---

TABLE 1 | Correlation between confocal imaging and histology.

| Confocal diagnosis | Sites | Histology |
|-------------------|-------|-----------|
|                   |       | Normal    | Adenoma | Adenocarcinoma |
| Normal            | 20    | 20        | 0       | 0              |
| Adenoma           | 25    | 2         | 22      | 1              |
| Adenocarcinoma    | 24    | 0         | 2       | 22             |

---
in vivo investigation, we are confident that topical administration of UEA-FITC would highlight adenoma and adenocarcinoma lesions in patients as well. Secondly, the relatively high cost and long learning curve of the procedure make it difficult for clinical use. Nevertheless, with the development of the economy and technology, we believe that it will be feasible in the near future. Thirdly, the actual advantages with respect to histology as the gold standard made this new approach more reliable, but it still could provide very reliable information.

In summary, we provide new concepts for identifying and validating molecular imaging targets for colorectal cancer. UEA can act as a cancer-specific imaging agent to improve the detection and treatment of CRC. The present imaging approach utilizes the simplicity of accessing the colorectal lumen, the well-established intraintestinal route for administering drugs in the colorectum, and the availability of clinical level imaging tools involving EC and CLE. We demonstrate that this method is feasible and may be adaptable for further development and validation of imaging agents in other hollow organs. Together, this research provides evidence for UEA as a colorectal cancer imaging target with the potential for clinical translation.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, Affiliated to the Huazhong University of Science and Technology. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, Affiliated to the Huazhong University of Science and Technology. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Chiu PWY, Uedo N, Singh R, Gotoda T, Ng EKW, Yao K, et al. An Asian Consensus on Standards of Diagnostic Upper Endoscopy for Neoplasia. *Gut* (2019) 68:186–97. doi: 10.1136/gutjnl-2018-317111
2. van der Sommen F, Curvers WL, Nagengast WB. Novel Developments in Endoscopic Mucosal Imaging. *Gastroenterology* (2018) 154:1876–86. doi: 10.1016/j.gastro.2018.01.070
3. Arnold M, Sierra MS, Lavrsanne M, Soerjomataram I, Jemal A, Bray F. Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. *Gut* (2017) 66:683–91. doi: 10.1136/gutjnl-2015-310912

AUTHOR CONTRIBUTIONS

WW and ST: Study design, manuscript preparation, statistical analysis, and study coordinator. XJ and SP: Animal experiment and data collection. HS, MF, and WJ: Patient experiment and data collection. ZW and WH: Animal data acquisition, and data analysis and interpretation. XX: Revising the manuscript. RL: Study design, manuscript revision, study supervision, and foundation support. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (Nos. 81900580, 81974068, and 81770539), the Natural Science Foundation of Hubei Province (No. 2017CFA061), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT330-003), and the Open Research Fund of NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases.

ACKNOWLEDGMENTS

The authors appreciate the language correction from Editage.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.792420/full#supplementary-material

Supplementary Figure 1 | Endoscopic molecular imaging of colorectal cancer using IgG-FITC and CLE in mouse and human.

Supplementary Video 1 | A video of CLE combined with UEA to detect normal colon tissue in mice CLE, confocal laser endomicroscopy; UEA, Ulex europaeus agglutinin.

Supplementary Video 2 | A video of CLE combined with UEA to detect colon adenoma tissue in mice CLE, confocal laser endomicroscopy; UEA, Ulex europaeus agglutinin.

Supplementary Video 3 | A video of CLE combined with UEA to detect colorectal cancer in mice CLE, confocal laser endomicroscopy; UEA, Ulex europaeus agglutinin.

1. Arnold M, Sierra MS, Lavrsanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2018) 68:394–424. doi: 10.3322/caac.21492
2. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Buttry LF, Anderson JC, et al. Colorectal Cancer Statistics, 2020. *CA Cancer J Clin* (2020) 70(3):145–64. doi: 10.3322/caac.21601
3. Fielitz M, Moss A, Hassan C, Bhandari P, Dumonceau JM, Papatsis G, et al. Colorectal Polypectomy and Endoscopic Mucosal Resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* (2017) 49:270–97. doi: 10.1055/s-0043-102569
18. Park SY, Lee SH, Kawasaki N, Itoh S, Kang K, Hee Ryu S, et al. Alpha1-3/4 Fucosylation at Asn 241 of Beta-Haptoglobin is a Novel Marker for Colon Cancer: A Combinatorial Approach for Development of Glycan Biomarkers. Int J Cancer (2012) 130(10):2366–76. doi: 10.1002/ijc.26288

19. Mishra A, Behura A, Mawatral S, Kumar A, Naik L, Mohanty SS, et al. Structure-Function and Application of Plant Lectins in Disease Biology and Immunity. Food Chem Toxicol (2019) 134:110827. doi: 10.1016/j.fct.2019.110827

20. di Pietro M, Bird-Lieberman EL, Liu X, Nuckcheddy-Grant T, Bertani H, O’Donovan M, et al. Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett’s Esophagus. Am J Gastroenterol (2013) 110(11):1549–58. doi: 10.1038/ajg.2013.295

21. Du Y, Fan K, Zhang H, Li L, Wang P, He J, et al. Endoscopic Molecular Imaging of Early Gastric Cancer Using Fluorescently Labeled Human H-Ferritin Nanoparticle. Nanomedicine (2018) 14:2259–70. doi: 10.1016/j.nano.2018.07.007

22. Shahid MW, Buchner AM, Raimondo M, Woodward TA, Krishna M, Wallace MB. Accuracy of Real-Time vs. Blinded Offline Diagnosis of Neoplastic Colorectal Polyps Using Probe-Based Confocal Laser Endomicroscopy: A Pilot Study. Endoscopy (2012) 44(7):343–8. doi: 10.1055/s-0031-1291589

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Tian, Jiang, Pang, Shi, Fan, Wang, Jiang, Hu, Xiao and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.